昂利康：2026年开始研发投入将更多聚焦创新药项目

Core Viewpoint - The company, Anglikang (002940), has indicated that after 2-3 years of intensive R&D investment, its planned generic drug projects are entering the output phase, with a gradual reduction in R&D spending on generics expected from 2026, shifting focus towards innovative drug projects [1] Group 1 - The company has been heavily investing in R&D for the past 2-3 years [1] - Generic drug projects are now starting to yield results [1] - From 2026, R&D investment in generics is expected to decrease [1] Group 2 - Future R&D efforts will increasingly concentrate on innovative drug projects [1]